Recent Research Funding

Our faculty secure major research grants from various National Institutes of Health as well as private sources.

  • Molecular mechanisms of skin immunity to Staphylococcal infection.Elizabeth Wohlfert (Co-Investigator). NIH. $3,520,304. 9/1/2021-8/1/2026.
  • MARCH Proteins, Members of a Host Protein Family that Targets HIV-1.Spyridon Stavrou (Principal Investigator). NIH. $1,974,920. 7/1/2021-6/1/2026.
  • T Regulatory cell responses in Toxoplasma-infected muscle.Elizabeth Wohlfert (Principal Investigator). NIAID/NIH. $2,445,371. 7/1/2021-6/1/2026.
  • Structure-based inhibitor design targeting SARS-CoV-2 protein-protein interfaces.Amy Jacobs (Co-Principal Investigator). NIAID. $996,875. 6/1/2021-5/1/2026.
  • The role of neutrophils in the age-driven decline in anti-pneumococcal vaccine responses.Elizabeth Wohlfert (Co-Investigator). NIH. $2,634,726. 4/1/2021-3/1/2026.
  • The in vivo functions of APOBEC3G.Spyridon Stavrou (Principal Investigator). NIH. $2,139,752. 9/1/2020-8/1/2025.
  • Bacterial sialometabolic activity impacts periodontal immunity and microbiota.Yijun Sun (Co-Investigator). NIH. $1,930,340. 9/1/2020-8/1/2025.
  • Evaluating antimicrobial photodynamic therapy as a novel treatment for Otitis Media.Anthony Campagnari (Principal Investigator). NIH/NIDCD. $1,952,905. 5/1/2021-4/1/2025.
  • Advanced computational approaches to delineating dynamic cancer progression processes by using massive static sample data.Yijun Sun (Principal Investigator). NIH. $1,964,300. 4/1/2020-3/1/2025.
  • The Organization and Function of the Toxoplasma Daughter Cell Scaffold.Ira Blader (Co-Principal Investigator). NIH. 1/1/2020-12/1/2024.
  • Conserved Proteus mirabilis genetic requirements for colonization of the catheterized urinary tract.Chelsie Armbruster (Principal Investigator). National Institute of Diabetes and Digestive and Kidney Diseases. 9/1/2019-5/1/2024.
  • Function and regulation of the essential RNA binding protein, DRBD18.Laurie Read (Principal Investigator). NIH. $2,121,078. 6/1/2019-5/1/2024.
  • SARS-CoV-2 genome instability and the effect of mutations on viral entry and infection.Amy Jacobs (Co-Investigator). NIAID. $437. 6/1/2021-7/1/2023.
  • Iterative preclinical validation of repurposed therapies against SARS-CoV-2 and COVID-19.Spyridon Stavrou (Co-Investigator). NIH. $714,347. 7/1/2021-6/1/2023.
  • The Translational Response of C. neoformans to Oxidative Stress and Macrophage Phagocytosis.Elizabeth Wohlfert (Co-Investigator). NIH. $447,863. 7/1/2021-6/1/2023.
  • Elucidating the role of 90K on SARS-CoV-2 infection.Spyridon Stavrou (Principal Investigator). NIH. $435,160. 6/1/2021-5/1/2023.
  • The role of heparanase during retrovirus infection.Spyridon Stavrou (Principal Investigator). NIH. $432,735. 4/1/2021-3/1/2023.
  • Features of PMN senescence that lead to susceptibility to pneumococcal infection.Elsa Bou Ghanem (Co-Investigator). NIA. $469,115. 3/1/2021-2/1/2023.
  • Elucidating the role of SERINC5 in SARS-CoV-2 infection.Spyridon Stavrou (Principal Investigator). NIH. $438,625. 10/1/2020-9/1/2022.
  • Electrical Stimulation for Infection Control of the Skin-Implant Interface of Osseointegrated Prostheses.Anthony Campagnari (Co-Investigator). Peer Reviewed Orthopedic Research Program of the Congressionally Directed Medical Research Program. $7,490,000. 9/1/2020-8/1/2022.